Dr. Saurabh Mehandru, MD

Dr. Mehandru practices at The Mount Sinai Hospital in New York, New York, part of Mount Sinai Health System.

Dr. Mehandru's NPI, 1972536035, was assigned on July 9, 2006. Dr. Mehandru holds New York license 243720.

Dr. Mehandru's primary practice is The Mount Sinai Hospital, at One Gustave L Levy Place, New York, NY 10029 in New York County. The practice phone is (212) 241-7981. Dr. Mehandru also practices at The Mount Sinai Hospital, 1 Gustave L Levy Pl, New York, NY 10029.

Dr. Mehandru's primary practice is The Mount Sinai Hospital in New York, New York, part of Mount Sinai Health System. The medical group on file is Mount Sinai Institute for Liver Medicine. Dmand AI also links Dr. Mehandru to 1 more group practice or clinic and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Mehandru practices, 2 sites in all. Vendor and product names are available with a free account.

Gastroenterology is Dr. Mehandru's primary specialty in the NPI Registry, under taxonomy code 207RG0100X. Dr. Mehandru is licensed in New York.

CMS data shows 90 Medicare services from Dr. Mehandru across 5 procedure codes in 2024, for 71 Medicare patients. Medicare paid $8,159 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 71 Medicare patients who saw Dr. Mehandru in 2024. The largest group is 65 to 74, with 32 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 35% are also on Medicaid. Their average risk score is 1.73, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Mehandru's median patient age at 54, with 43% women.

In 2024, Dr. Mehandru wrote 120 Medicare Part D claims for 53 patients. 88% of them were for generic drugs. CMS names the drug for 89 of them, across 4 drugs with 11 or more claims each, at $6,550 in total drug cost. In 2023, CMS named 71 claims across 2 drugs.

Dr. Mehandru accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Mehandru as offering telehealth. CMS counts 31 procedures of colonoscopy by Dr. Mehandru, more than 54% of the clinicians it reports for that procedure.

Dmand AI links 75 papers to Dr. Mehandru, published from 2011 to 2025. 2020 was the busiest year, with 10. The most frequent topics are Inflammatory Bowel Diseases, Colitis, Ulcerative and Intestinal Mucosa. Dr. Mehandru has published most often in Nat Rev Gastroenterol Hepatol. Dr. Mehandru's most frequent co-authors are Ryan Colin Ungaro, Francesca Cossarini and Judy Cho, MD.

Dmand AI links Dr. Mehandru to 1 clinical trial. Conditions studied include Autoimmune Diseases and Immune System Diseases. Open Payments lists research payments to Dr. Mehandru that name 1 trial.

CMS Open Payments shows 49 general payments to Dr. Mehandru from 11 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 94% of the total. GlaxoSmithKline, LLC. paid the most, $24,378. It also lists 2 research payments totaling $900 in 2021, naming 1 clinical trial.